WAYFIND-R: Delivering a high-quality real-world data (RWD) global registry of patients diagnosed with a solid tumor and profiled with next-generation sequencing (NGS)

Christophe Le Tourneau, Allan Hackshaw, Jean-Yves Blay, Jan Geissler, Rodrigo Dienstmann, Martina von Meyern, Clare Turnbull, Olga Skatkova, Martina von Meyern, Rodrigo Dienstmann

1 Institut Curie, Paris, France; 2 UCL Cancer Institute, London, UK; 3 Centre Léon Bérard, Lyon, France; 4 Patvocates, Munich, Germany; 5 The Institute of Cancer Research, London, UK; 6 F. Hoffmann-La Roche Ltd, Basel, Switzerland; 7 Oncoclínicas Precision Medicine, Oncoclínicas Grupo, São Paulo, Brazil

Summary

WAYFIND-R will inform on best practice for NGS-based treatment decisions by clinicians, foster global collaborations between cancer centers (enabling robust conclusions to be drawn regarding outcome data), aid understanding of disparities in patients’ access to advanced diagnostics and therapies, and ultimately drive advances in precision oncology.

Eligibility criteria

- Adults with any type/stage of solid tumor who have been profiled with NGS (all clinically validated tests of any size)
- Academic centers, community hospitals, and private clinics with regular MTBs and where NGS is common practice
- Prior or current diagnosis of a hematologic malignancy

Conflicts of interest

CLT has received grants/contracts from MSK, has received travel expenses from MSK, BMS, and AstraZeneca, has received honoraria from and performed a consulting/advisory role for BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK, Rambus, Seattle Genetics, and AstraZeneca, and has served as an external consultant. Please refer to the Supplement for all author conflicts of interest. This analysis was sponsored by F. Hoffmann-La Roche Ltd.

WAYFIND-R (NCT04529122), a global, prospective, longitudinal, generalizable registry, with NGS and standardized data collection to enhance data quality and limit data missingness

1. Rare molecular cancer subtypes and evolving biomarker knowledge pose difficulties in traditional clinical trials for NGS-based molecular therapy
2. Collecting RWD from patients can help to elucidate the effectiveness of targeted therapies, MTBs, and NGS-based genomic profiling

1. Characterizes the treatments and clinical course of patients with solid tumors
2. Provides a data research platform to evaluate real-world treatment decisions and outcomes
3. Supports the design and conduct of epidemiologic research and clinical trials
4. Reveals key learnings on data quality, sharing, and privacy for contemporary disease registries

Eligibility criteria

- Prior or current diagnosis of a hematologic malignancy

Conflict of interest

CLT has received grants/contracts from MSK, has received travel expenses from MSK, BMS, and AstraZeneca, has received honoraria from and performed a consulting/advisory role for BMS, MSD, Merck Serono, Roche, Nanobiotix, GSK, Rambus, Seattle Genetics, and AstraZeneca, and has served as an external consultant. Please refer to the Supplement for all author conflicts of interest. This analysis was sponsored by F. Hoffmann-La Roche Ltd.

WAYFIND-R (NCT04529122) is a global, prospective, longitudinal, generalizable registry, with NGS and standardized data collection to enhance data quality and limit data missingness.